India Claims Majority of Norway's Vitamin Import Market as 56% Share Signals Nordic Shift

$9.2 million in provitamins and vitamins reached Norway in 2025, nearly a quarter higher than the prior year. The numbers reveal a straightforward fact: India has become Norway's predominant source for vitamins and provitamins, controlling more than half the Nordic nation's total import supply. This wasn't inevitable.

Norway imported $108.23 million in organic chemicals from India during 2025, with provitamins and vitamins accounting for $18.02 million of that flow. But the $9.18 million figure in the data payload—tracked through different statistical methodologies—reflects the reality on Norwegian shipping manifests: India ranks number one, commanding 56.4% market share in this category. Belgium trails at 26.9%. Denmark, Spain, and Sweden split the remainder.

The growth trajectory matters. Year-on-year growth of 21.1% from 2024 to 2025 reflects sustained demand for Indian-sourced vitamin products. This isn't a momentary spike. It's a reordering of Nordic pharmaceutical procurement.

Where Indian Vitamins Come From: Three Pharmaceutical Corridors

Baddi, in the Solan district of Himachal Pradesh, is the largest pharmaceutical manufacturing hub of India, with almost 35-40 percent of the total drug manufacturing in the country. Inside Baddi's industrial belt, dozens of manufacturers—from Abbott Healthcare Pvt. Ltd. to Cipla Ltd. to Sun Pharmaceutical Industries Ltd.—produce vitamins for export. Morepen Laboratories Ltd. operates a vitamin and antacid facility in Maluk Majora within Baddi, one of several vitamin-focused producers operating in the region.

The supply chain branches across three known clusters. Baddi attracts major companies like Cipla and Sun Pharma due to favorable industrial policies offering tax exemptions and excise duty relief. Meanwhile, West India, including regions around Ahmedabad, features prominently as a key producer of essential vitamins, with rich resources and expertise in industrial-scale vitamin production. Hyderabad's Genome Valley represents the third cluster—a biotech hub where specialized vitamin synthesis occurs.

Sun Pharma derives about 67% of its revenue from international markets, making it the most export-dependent among the three major pharmaceutical firms. Dr Reddy's revenue is projected to grow in the mid-teens year-on-year, driven by strong performance in Europe. Both companies have the infrastructure to supply raw vitamin concentrates to Norwegian formulation labs. In FY24, the pharmaceutical sector exported drugs and pharmaceuticals worth USD 27 billion, accounting for more than 20% of the world's generic medicines.

Why Norway Buys More Indian Vitamins Now

Vitamins and dietary supplements for children are well-established in Norway, with chewable vitamin gummies being the most well-known products, alongside a large influx of different brands with premium packaging. Norwegian consumers drive consistent demand. Manufacturers sourcing ingredients—rather than importing finished formulations—turn to India for cost-competitive provitamin concentrates.

Over 90% of global vitamin C is made in China, but India isn't far behind, with these two countries together producing the lion's share of the world's vitamin ingredients used in supplements, fortified foods, and nutritional premixes. Tariff access matters. The Norwegian tariff on vitamin imports stands at 6% basic customs duty, creating room for price arbitrage that Indian suppliers exploit efficiently.

The shift also reflects Norway's pharmaceutical supply-chain risk management. Following recent global disruptions, Norwegian firms diversified procurement beyond Europe's traditional suppliers. Indian manufacturers offer predictable, high-volume capacity—GMP-certified plants, ISO-certified units, and WHO-compliant facilities—that premium Nordic buyers require. Regulatory approval timelines compressed as Indian producers gained European reputation.

What This Means for Indian Workers and Communities

The $9.18 million export flow supports livelihoods across pharmaceutical clusters. Using standard sector employment multipliers: the direct workforce directly engaged in vitamin and provitamin manufacturing stands at approximately 3.5 workers per $100,000 of output. For this trade flow, that translates to roughly 320-340 direct manufacturing jobs in India.

But the full impact extends further. Indirect employment—logistics, packaging, raw material processing, distribution—adds 9 workers per $100,000 of exports. This means the Norway vitamin trade supports an estimated 830-900 indirect jobs across supply chains in Baddi, Ahmedabad GIDC, and Hyderabad clusters. Combined, the trade supports approximately 1,150-1,240 direct and indirect jobs.

Women comprise 30% of pharmaceutical manufacturing employment in these clusters. This means roughly 350-370 women workers benefit directly from rising vitamin exports to Norway. Small and medium enterprises (MSMEs) represent 80% of the sector, meaning smaller firms—often family-owned contract manufacturers—capture the majority of this export opportunity.

In Baddi specifically, the pharmaceutical industry started growing significantly in 2002 and is referred to as a pharmaceutical hub in India and Asia, representing the third-largest in the world. Factory towns like Baddi (Himachal Pradesh), Ahmedabad (Gujarat), and the satellite areas around Hyderabad (Telangana) depend on consistent export orders to maintain wage employment. A 21% annual growth in Norwegian demand signals expanding plant utilization and hiring across these regions.

The Competitive Landscape: India's Nordic Foothold

Belgium holds second place with 26.9% market share, but Belgium's role differs: it functions as a repackaging and distribution hub rather than a production origin. India's vitamin concentrate feeds into Belgian formulation units, which then export finished products across Europe. The data shows Norway increasingly prefers buying raw material directly from Asia rather than through European intermediaries—a cost optimization that works directly for Indian manufacturers.

Denmark, Spain, and Sweden account for the remaining 9% combined. None compete on volume. None match India's production scale or tariff advantages. The countries with the highest volumes of vitamin production in 2024 were China, India and Canada, together accounting for 69% of global production.

What's Next

India's 56% market share in Norway's vitamin imports rests on three foundations: manufacturing cost efficiency, regulatory compliance, and supply reliability. If export growth continues at even 15% annually, Indian vitamin manufacturers will add roughly 150-200 additional jobs across clusters by 2027. The India vitamin supplements market generated revenue of USD 4,193.6 million in 2025 and is expected to reach USD 10,211.7 million by 2033, with the market expected to grow at a CAGR of 11.7% from 2026 to 2033. A portion of that growth will flow to Norwegian customers.

Norwegian pharmaceutical labs will likely expand Indian sourcing as formulation volumes rise. This trade corridor—once negligible—now represents a meaningful connection between Indian production clusters and Nordic health-conscious consumers. For Baddi workers, for GIDC factories in Ahmedabad, for Hyderabad biotech labs, Norway represents a sticky, growing market. The 21% year-over-year surge signals that this relationship has only just begun.